141 related articles for article (PubMed ID: 38722799)
1. Design of FK866-Based Degraders for Blocking the Nonenzymatic Functions of Nicotinamide Phosphoribosyltransferase.
Lu T; Chen F; Yao J; Bu Z; Kyani A; Liang B; Chen S; Zheng Y; Liang H; Neamati N; Liu Y
J Med Chem; 2024 May; 67(10):8099-8121. PubMed ID: 38722799
[TBL] [Abstract][Full Text] [Related]
2. Crystal structure-based comparison of two NAMPT inhibitors.
Zhang SL; Xu TY; Yang ZL; Han S; Zhao Q; Miao CY
Acta Pharmacol Sin; 2018 Feb; 39(2):294-301. PubMed ID: 28858298
[TBL] [Abstract][Full Text] [Related]
3. Fragment-based discovery of a potent NAMPT inhibitor.
Korepanova A; Longenecker KL; Pratt SD; Panchal SC; Clark RF; Lake M; Gopalakrishnan SM; Raich D; Sun C; Petros AM
Bioorg Med Chem Lett; 2018 Feb; 28(3):437-440. PubMed ID: 29287958
[TBL] [Abstract][Full Text] [Related]
4. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition.
Cea M; Cagnetta A; Fulciniti M; Tai YT; Hideshima T; Chauhan D; Roccaro A; Sacco A; Calimeri T; Cottini F; Jakubikova J; Kong SY; Patrone F; Nencioni A; Gobbi M; Richardson P; Munshi N; Anderson KC
Blood; 2012 Oct; 120(17):3519-29. PubMed ID: 22955917
[TBL] [Abstract][Full Text] [Related]
5. Leukocyte Overexpression of Intracellular NAMPT Attenuates Atherosclerosis by Regulating PPARγ-Dependent Monocyte Differentiation and Function.
Bermudez B; Dahl TB; Medina I; Groeneweg M; Holm S; Montserrat-de la Paz S; Rousch M; Otten J; Herias V; Varela LM; Ranheim T; Yndestad A; Ortega-Gomez A; Abia R; Nagy L; Aukrust P; Muriana FJG; Halvorsen B; Biessen EAL
Arterioscler Thromb Vasc Biol; 2017 Jun; 37(6):1157-1167. PubMed ID: 28408371
[TBL] [Abstract][Full Text] [Related]
6. FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells.
Schuster S; Penke M; Gorski T; Gebhardt R; Weiss TS; Kiess W; Garten A
Biochem Biophys Res Commun; 2015 Mar; 458(2):334-40. PubMed ID: 25656579
[TBL] [Abstract][Full Text] [Related]
7. Genomic and tumor biological aspects of the anticancer nicotinamide phosphoribosyltransferase inhibitor FK866 in resistant human colorectal cancer cells.
Ogino Y; Sato A; Uchiumi F; Tanuma SI
Genomics; 2019 Dec; 111(6):1889-1895. PubMed ID: 30582964
[TBL] [Abstract][Full Text] [Related]
8. CD73 protein as a source of extracellular precursors for sustained NAD+ biosynthesis in FK866-treated tumor cells.
Grozio A; Sociali G; Sturla L; Caffa I; Soncini D; Salis A; Raffaelli N; De Flora A; Nencioni A; Bruzzone S
J Biol Chem; 2013 Sep; 288(36):25938-25949. PubMed ID: 23880765
[TBL] [Abstract][Full Text] [Related]
9. Nicotinamide phosphoribosyltransferase may be involved in age-related brain diseases.
Liu LY; Wang F; Zhang XY; Huang P; Lu YB; Wei EQ; Zhang WP
PLoS One; 2012; 7(10):e44933. PubMed ID: 23071504
[TBL] [Abstract][Full Text] [Related]
10. A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT.
Barraud M; Garnier J; Loncle C; Gayet O; Lequeue C; Vasseur S; Bian B; Duconseil P; Gilabert M; Bigonnet M; Maignan A; Moutardier V; Garcia S; Turrini O; Delpero JR; Giovannini M; Grandval P; Gasmi M; Ouaissi M; Secq V; Poizat F; Guibert N; Iovanna J; Dusetti N
Oncotarget; 2016 Aug; 7(33):53783-53796. PubMed ID: 27462772
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT), an Enzyme Essential for NAD+ Biosynthesis, Leads to Altered Carbohydrate Metabolism in Cancer Cells.
Tan B; Dong S; Shepard RL; Kays L; Roth KD; Geeganage S; Kuo MS; Zhao G
J Biol Chem; 2015 Jun; 290(25):15812-15824. PubMed ID: 25944913
[TBL] [Abstract][Full Text] [Related]
12. NAMPT inhibitor and metabolite protect mouse brain from cryoinjury through distinct mechanisms.
Zhang XQ; Lu JT; Jiang WX; Lu YB; Wu M; Wei EQ; Zhang WP; Tang C
Neuroscience; 2015 Apr; 291():230-40. PubMed ID: 25684751
[TBL] [Abstract][Full Text] [Related]
13. Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
Travelli C; Aprile S; Mattoteia D; Colombo G; Clemente N; Scanziani E; Terrazzino S; Alisi MA; Polenzani L; Grosa G; Genazzani AA; Tron GC; Galli U
Eur J Med Chem; 2019 Nov; 181():111576. PubMed ID: 31400709
[TBL] [Abstract][Full Text] [Related]
14. Regulation of the Nampt-mediated NAD salvage pathway and its therapeutic implications in pancreatic cancer.
Ju HQ; Zhuang ZN; Li H; Tian T; Lu YX; Fan XQ; Zhou HJ; Mo HY; Sheng H; Chiao PJ; Xu RH
Cancer Lett; 2016 Aug; 379(1):1-11. PubMed ID: 27233476
[TBL] [Abstract][Full Text] [Related]
15. EWS-FLI1 confers exquisite sensitivity to NAMPT inhibition in Ewing sarcoma cells.
Mutz CN; Schwentner R; Aryee DNT; Bouchard EDJ; Mejia EM; Hatch GM; Kauer MO; Katschnig AM; Ban J; Garten A; Alonso J; Banerji V; Kovar H
Oncotarget; 2017 Apr; 8(15):24679-24693. PubMed ID: 28160567
[TBL] [Abstract][Full Text] [Related]
16. Addressing the Enzyme-independent tumor-promoting function of NAMPT via PROTAC-mediated degradation.
Zhu X; Liu H; Chen L; Wu C; Liu X; Cang Y; Jiang B; Yang X; Fan G
Cell Chem Biol; 2022 Nov; 29(11):1616-1629.e12. PubMed ID: 36323324
[TBL] [Abstract][Full Text] [Related]
17. Nicotinamide phosphoribosyltransferase and the hypothalamic-pituitary-adrenal axis of the rat.
Celichowski P; Jopek K; Milecka P; Szyszka M; Tyczewska M; Malendowicz LK; Ruciński M
Mol Med Rep; 2018 Apr; 17(4):6163-6173. PubMed ID: 29436637
[TBL] [Abstract][Full Text] [Related]
18. Nicotinamide phosphoribosyltransferase: a potent therapeutic target in non-small cell lung cancer with epidermal growth factor receptor-gene mutation.
Okumura S; Sasaki T; Minami Y; Ohsaki Y
J Thorac Oncol; 2012 Jan; 7(1):49-56. PubMed ID: 22089115
[TBL] [Abstract][Full Text] [Related]
19. Antitumor effect of combined NAMPT and CD73 inhibition in an ovarian cancer model.
Sociali G; Raffaghello L; Magnone M; Zamporlini F; Emionite L; Sturla L; Bianchi G; Vigliarolo T; Nahimana A; Nencioni A; Raffaelli N; Bruzzone S
Oncotarget; 2016 Jan; 7(3):2968-84. PubMed ID: 26658104
[TBL] [Abstract][Full Text] [Related]
20. Extracellular Nampt promotes macrophage survival via a nonenzymatic interleukin-6/STAT3 signaling mechanism.
Li Y; Zhang Y; Dorweiler B; Cui D; Wang T; Woo CW; Brunkan CS; Wolberger C; Imai S; Tabas I
J Biol Chem; 2008 Dec; 283(50):34833-43. PubMed ID: 18945671
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]